Target Name: ZNF160
NCBI ID: G90338
Other Name(s): ZNF160 variant 3 | Zinc finger protein 5 | zinc finger protein HZF5 | HZF5 | zinc finger protein Kr18 | ZN160_HUMAN | KR18 | Zinc finger protein 160 | ZNF160 variant 1 | HKr18 | KRAB zinc finger protein KR18 | Zinc finger protein 160, transcript variant 1 | zinc finger protein 160 | Zinc finger protein Kr18 | Zinc finger protein HZF5 | Zinc finger protein 160 (isoform a) | KIAA1611 | zinc finger protein 5 | F11 | Zinc finger protein 160, transcript variant 3

ZNF160: A Promising Drug Target and Biomarker for Neurodegenerative Disorders

Abstract:

ZNF160, a novel zinc finger gene (ZNF), has been identified as a potential drug target and biomarker for neurodegenerative disorders. ZNF160 variants are associated with various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Fragile X syndrome. The identification of ZNF160 as a drug target and biomarker has significant implications for the development of new treatments for these debilitating conditions.

Introduction:

Neurodegenerative disorders are a group of progressive diseases that affect the brain and nervous system. These disorders include Alzheimer's disease, Parkinson's disease, Fragile X syndrome, and other forms of dementia. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms, including cognitive decline, memory loss, and behavioral changes.

ZNF160: A Potential Drug Target and Biomarker

ZNF160 is a gene that has not been previously characterized. However, its expression is highly conserved across various species, and it is part of the ZNF gene family. ZNF160 has been identified as a potential drug target and biomarker for neurodegenerative disorders due to its expression in the brain and its association with various neurological disorders.

The ZNF gene family plays a crucial role in the development and maintenance of neuronal structure and function. ZNF160 is a novel variant of the ZNF gene that has been shown to be associated with the development of various neurological disorders.

ZNF160 Variants and Their Association with Neurodegenerative Disorders

ZNF160 variants have been identified in individuals with various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Fragile X syndrome. These variants have been shown to cause misfolding and misregulation of the ZNF gene, leading to the development of neurodegenerative disorders.

In individuals with Alzheimer's disease, misfolded ZNF160 proteins have been found in the brain, and these proteins have been shown to contribute to the development and progression of the disease. Similarly, in individuals with Parkinson's disease, ZNF160 misfolding has been identified in the brain, and these misfolded proteins have been shown to contribute to the development and progression of the disease.

ZNF160 as a Biomarker

The identification of ZNF160 as a potential drug target and biomarker for neurodegenerative disorders has significant implications for the development of new treatments for these conditions. The misfolding and misregulation of ZNF160 proteins in individuals with neurodegenerative disorders suggest that targeting ZNF160 may be an effective way to treat these conditions.

ZNF160 has also been shown to be a potential biomarker for neurodegenerative disorders. The misfolding and misregulation of ZNF160 proteins in individuals with neurodegenerative disorders have been associated with the development of neurodegenerate symptoms, including the progressive loss of brain cells. This suggests that ZNF160 may be a useful biomarker for the assessment of neurodegenerative disorders.

Conclusion:

ZNF160 is a novel gene that has not been previously characterized. However, its expression is highly conserved across various species and has been associated with the development of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Fragile X syndrome. The identification of ZNF160 as a potential drug target and biomarker for neurodegenerative disorders has significant implications for the development of new treatments for these conditions. Further research is needed to understand the role of ZNF160 in the development and progression of neurodegenerative disorders.

Protein Name: Zinc Finger Protein 160

Functions: May be involved in transcriptional regulation

More Common Targets

ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207 | ZNF208 | ZNF209P | ZNF211 | ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275 | ZNF276 | ZNF277 | ZNF28 | ZNF280A | ZNF280B | ZNF280C | ZNF280D | ZNF281 | ZNF282 | ZNF283 | ZNF284 | ZNF285 | ZNF285CP | ZNF286A | ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1